{"id":534679,"date":"2021-09-07T07:33:19","date_gmt":"2021-09-07T11:33:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/"},"modified":"2021-09-07T07:33:19","modified_gmt":"2021-09-07T11:33:19","slug":"crinetics-pharmaceuticals-to-participate-in-september-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/","title":{"rendered":"Crinetics Pharmaceuticals to Participate in September Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Sept.  07, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L5JbOTLSTP4ws0EtKeNIbqtlZJ7NOzvyet0D9-mA8HpBWHxaFU6YsL_TOiQtiGEgrJ342DgdDOlPXPAhMDzcQFEECrWsMzIp5S21ketPRoa2mYOSsqVDdr3MZn0K12e1OpgganBF-jnJpx9TH9LJ_N67z1kGrSLnhPt7Wbm5HNpuKdwqTy26g7rJFETNAtIv\" rel=\"nofollow noopener\" target=\"_blank\">Crinetics Pharmaceuticals<\/a> (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in the following investor conferences in the month of September:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>H.C. Wainwright: 23<\/strong><br \/>\n          <sup><br \/>\n            <strong>rd<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Global Investment Conference (September 13-15, 2021):<\/strong> A pre-recorded company presentation by Dr. Scott Struthers,\u00a0Founder &amp; CEO, will be available on-demand for approximately 30 days beginning September 13, 2021 at 7:00 am ET. Company management will also be available for one-on-one meetings at the conference on September 13, 2021.<\/p>\n<\/li>\n<li>\n          <strong>SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event (September 22-23, 2021):<\/strong> Company management will be available for one-on-one meetings on September 22, 2021. <\/p>\n<\/li>\n<li>\n          <strong>Cantor Fitzgerald: Global Healthcare Conference (September 27-30, 2021):<\/strong> Dr. Struthers and Dr. Alan Krasner, CMO, will present on September 27, 2021 at 3:20 pm ET and participate in one-on-one meetings on September 27-28, 2021.<\/li>\n<\/ul>\n<p>\n        <strong>Webcast Links: <\/strong><br \/>\n        <br \/>Links to live and archived webcasts will be accessible on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WRTHAEAd0lTkHyUegZ-nbK7riuNXnnmjoZV5ZdMoF1SkUHpc9Wa8gzT7xt28uukQyR5Mq39HKJJiyWFbiHOd3wAVQpZRlMZuj17Y8xNbUQIhF0s3fQkkiBQ2mE8OR0G-I4ugb1oHV7vIgpfnfHqOCHrxigsjVcC3iZU4JDlX-RnZXXTeNqRUjicEoWf7BHKo\" rel=\"nofollow noopener\" target=\"_blank\">Events &amp; Presentations<\/a> page in the Investors section on the Company\u2019s website.<\/p>\n<p>\n        <strong>About Crinetics Pharmaceuticals<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L5JbOTLSTP4ws0EtKeNIbqtlZJ7NOzvyet0D9-mA8Hrzzm8LZq-VdRZG6fupK8Eh9kvH8pCE9w-N3S2qzZMg7UGQx_VUgq4VsbdrgBuyZMLAwXjJb_RmqSjwQ9ZUuewTbr--Ql-An5un1mJPjapc0hURTQUTADsW8Jst6LHbh-k=\" rel=\"nofollow noopener\" target=\"_blank\">Crinetics Pharmaceuticals<\/a> is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company\u2019s lead product candidate, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=o19feYbJd0-WUs7nGqZzPKvSpHCGAwplt36lKX0KvniY_274upkU95gb6JqSOi3hrkCJjjIXDtwk3VrL_1NvchqpA6o1nZln3iLlVB0nELd7W0As_1Q_kCPxhkqCLLeTdfK_L9u9QbOBJxw7KkQjpCs5tV4WVAu4KWYMDYENcX3mNdPfD2HyFHGH4Nu2i_vHD1zIGZ0kRV5GTxNaHkq34A==\" rel=\"nofollow noopener\" target=\"_blank\">paltusotine<\/a> (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase\u00a03 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FpYP3z8nfQ7DTvYHTYHkQTrjJQ43H6OmV8LQi7xnDPQh2Si8xQ6t_Iu-tx5USa_nPGxCp56_cY3efDymdc3VPmJILOSOEfUjxvoSRakEqTqbv7jhPfwyrNPpegB8ZWkkqeXkH_GJqN4wPtuHqkny4-NHGTPqayLzrFeVw1qDwPyB_VCpDbm4x-lsGsWzYaBKs0z2v9VngDoLPkjqCBmn_fBspddx6GEhq1apdnRnnosj8F3lBWtmtwsphKIqNZjV\" rel=\"nofollow noopener\" target=\"_blank\">CRN04777<\/a>, an investigational, oral, nonpeptide somatostatin receptor type\u00a05 (SST5) agonist for congenital hyperinsulinism, as well as <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kG9RWhmYMKOAg77n_imNFrL1Y4fvWt2_eNyZ9i9RjLRPSxH8huj3RW3dovevjV0rTzoLuHm4FRil4K6BQh24d7I508qaVKITcNsJjc-mRTAxIp2Sf7X85scjill0MwDg5RLT10g9gLLhfi28z83Swt9r0PmoFYmmMStek06H3oWNNXJNEpyb7MwAC6ToFsrNOtgcZ8Z6D7K4jIt7Er5uvw==\" rel=\"nofollow noopener\" target=\"_blank\">CRN04894<\/a>, an investigational, oral, nonpeptide ACTH antagonist for the treatment of Cushing\u2019s disease, congenital adrenal hyperplasia, and other diseases of excess ACTH. All of the company\u2019s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.<\/p>\n<p>\n        <strong>Contacts: <\/strong><br \/>\n        <br \/>Marc Wilson <br \/>Chief Financial Officer <br \/>IR@crinetics.com <br \/>(858) 450-6464<\/p>\n<p>Investors \/ Media: <br \/>Corey Davis <br \/>LifeSci Advisors, LLC <br \/>cdavis@lifesciadvisors.com<br \/>(212) 915-2577<\/p>\n<p>Aline Sherwood <br \/>Scienta Communications <br \/>asherwood@scientapr.com<br \/>(312) 238-8957<\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDI1OSM0Mzg4ODk4IzIwODk4MTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NGE4MzJhYjgtYTI3MC00ZDU4LWE0NmItMjY0NGQxMGUxZmU4LTExMDEzODY=\/tiny\/Crinetics-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) &#8212; Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in the following investor conferences in the month of September: H.C. Wainwright: 23 rd Annual Global Investment Conference (September 13-15, 2021): A pre-recorded company presentation by Dr. Scott Struthers,\u00a0Founder &amp; CEO, will be available on-demand for approximately 30 days beginning September 13, 2021 at 7:00 am ET. Company management will also be available for one-on-one meetings at the conference on September 13, 2021. SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event (September 22-23, 2021): Company management &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Crinetics Pharmaceuticals to Participate in September Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534679","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Crinetics Pharmaceuticals to Participate in September Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Crinetics Pharmaceuticals to Participate in September Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) &#8212; Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in the following investor conferences in the month of September: H.C. Wainwright: 23 rd Annual Global Investment Conference (September 13-15, 2021): A pre-recorded company presentation by Dr. Scott Struthers,\u00a0Founder &amp; CEO, will be available on-demand for approximately 30 days beginning September 13, 2021 at 7:00 am ET. Company management will also be available for one-on-one meetings at the conference on September 13, 2021. SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event (September 22-23, 2021): Company management &hellip; Continue reading &quot;Crinetics Pharmaceuticals to Participate in September Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-07T11:33:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDI1OSM0Mzg4ODk4IzIwODk4MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Crinetics Pharmaceuticals to Participate in September Investor Conferences\",\"datePublished\":\"2021-09-07T11:33:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\\\/\"},\"wordCount\":372,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDI1OSM0Mzg4ODk4IzIwODk4MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\\\/\",\"name\":\"Crinetics Pharmaceuticals to Participate in September Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDI1OSM0Mzg4ODk4IzIwODk4MTU=\",\"datePublished\":\"2021-09-07T11:33:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDI1OSM0Mzg4ODk4IzIwODk4MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDI1OSM0Mzg4ODk4IzIwODk4MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Crinetics Pharmaceuticals to Participate in September Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Crinetics Pharmaceuticals to Participate in September Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Crinetics Pharmaceuticals to Participate in September Investor Conferences - Market Newsdesk","og_description":"SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) &#8212; Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in the following investor conferences in the month of September: H.C. Wainwright: 23 rd Annual Global Investment Conference (September 13-15, 2021): A pre-recorded company presentation by Dr. Scott Struthers,\u00a0Founder &amp; CEO, will be available on-demand for approximately 30 days beginning September 13, 2021 at 7:00 am ET. Company management will also be available for one-on-one meetings at the conference on September 13, 2021. SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event (September 22-23, 2021): Company management &hellip; Continue reading \"Crinetics Pharmaceuticals to Participate in September Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-07T11:33:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDI1OSM0Mzg4ODk4IzIwODk4MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Crinetics Pharmaceuticals to Participate in September Investor Conferences","datePublished":"2021-09-07T11:33:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/"},"wordCount":372,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDI1OSM0Mzg4ODk4IzIwODk4MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/","name":"Crinetics Pharmaceuticals to Participate in September Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDI1OSM0Mzg4ODk4IzIwODk4MTU=","datePublished":"2021-09-07T11:33:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDI1OSM0Mzg4ODk4IzIwODk4MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDI1OSM0Mzg4ODk4IzIwODk4MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Crinetics Pharmaceuticals to Participate in September Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534679"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534679\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}